Clinical Trial Update: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ofatumumab with bortezomib in previously untreated Waldenström macroglobulinemia was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Waldenström Macroglobulinemia | Phase 2 | Status: TERMINATED | Results posted: 2016-06-10